NovaBridge Biosciences Insider Trades
NASDAQ: NBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 3 · $663.18K
- Sales
- 7 · $154.27K
- Shares bought / sold
- 460.00K / 157.34K
- Net activity
- Net buying $508,909
NovaBridge Biosciences insider activity
Over the last 12 months, NovaBridge Biosciences insiders reported 19 transactions on SEC Form 4: 3 open-market purchases and 7 sales. Insiders bought $663,182 and sold $154,273 worth of stock, for net insider buying of $508,909. The largest seller was Cao Sean Wuxiong, with $122,488 in reported sales.
The most recent filing shows Hagler Mark Arnold (Chief Commercial Officer) buying 184,000 shares at $0.381 on Nov 18, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put NBP's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
NBP insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 18, 2026 | Hagler Mark ArnoldChief Commercial Officer | Buy | 184,000 | $70.10K | Form 4 |
| Nov 17, 2026 | Hagler Mark ArnoldChief Commercial Officer | Buy | 46,000 | $15.78K | Form 4 |
| Oct 15, 2026 | Woo Ian YingDirector | Option exercise | 13,271 | — | Form 4 |
| Sep 18, 2026 | Dennis Phillip AndrewChief Medical Officer | Sale | 8,209 | $5.83K | Form 4 |
| Sep 17, 2026 | Dennis Phillip AndrewChief Medical Officer | Option exercise | 23,695 | — | Form 4 |
| Sep 9, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Sale | 107,978 | $79.90K | Form 4 |
| Sep 3, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Option exercise | 104,236 | — | Form 4 |
| Sep 3, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Option exercise | 235,136 | — | Form 4 |
| Aug 31, 2026 | Xu Cong ClaireEVP, Clinical Development | Sale | 3,282 | $2.59K | Form 4 |
| Aug 30, 2026 | Xu Cong ClaireEVP, Clinical Development | Option exercise | 9,382 | — | Form 4 |
| Aug 22, 2026 | Lenz Robert A.Director | Option exercise | 17,218 | — | Form 4 |
| Jul 6, 2026 | Xu Cong ClaireSVP, Clinical Development | Sale | 4,485 | $3.99K | Form 4 |
| Jul 4, 2026 | Xu Cong ClaireSVP, Clinical Development | Option exercise | 12,432 | — | Form 4 |
| Jun 18, 2026 | Dennis Phillip AndrewChief Medical Officer | Sale | 8,494 | $5.61K | Form 4 |
| Jun 17, 2026 | Dennis Phillip AndrewChief Medical Officer | Option exercise | 23,695 | — | Form 4 |
| Jun 1, 2026 | Xu Cong ClaireSVP, Clinical Development | Sale | 3,494 | $13.77K | Form 4 |
| May 30, 2026 | Xu Cong ClaireSVP, Clinical Development | Option exercise | 9,382 | — | Form 4 |
| May 14, 2026 | Cao Sean WuxiongSee Remarks | Sale | 21,399 | $42.58K | Form 4 |
| Apr 24, 2026 | Hagler Mark ArnoldSee Remarks | Buy | 230,000 | $577.30K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4